Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 61.50 [6]. Core Insights - The company reported total revenue of RMB 107.34 billion for 2H25, a year-on-year increase of 26.3%, and an annual revenue of RMB 201.90 billion, up 37.7%, slightly below expectations by 2% [1]. - Core ride-hailing service revenue reached RMB 99.64 billion, growing 27.3% year-on-year, driven by a significant increase in monthly active users (MAU) and active drivers [2][3]. - The adjusted net loss for 2H25 was RMB -1.79 billion, with an annual adjusted net loss of RMB -5.08 billion, narrowing by 29.8%, exceeding expectations by 10% [2]. Revenue Growth - The core ride-hailing service revenue of RMB 99.64 billion was primarily driven by a 43.9% year-on-year increase in MAU and a 35.4% increase in average monthly active drivers [2]. - The Gross Transaction Value (GTV) for 2H25 reached RMB 124.73 billion, reflecting a year-on-year growth of 27.0% [3]. User Expansion and Market Penetration - The company has expanded its services to 195 cities, adding 59 new cities, which has improved supply-demand matching efficiency in tier-3 and tier-4 markets [3]. - The increase in user MAU and active drivers indicates enhanced penetration and user stickiness across the country [3]. Robotaxi Strategy - The company is advancing its Robotaxi strategy, having launched the Caocao Smart Mobility platform and deployed Robotaxi pilot programs in early 2025, with plans for mass production by 2027 [4]. - The company aims to expand its Robotaxi operations internationally, with plans for initial operations in Abu Dhabi and Hong Kong [4]. Financial Projections - Revenue projections for 2026, 2027, and 2028 are RMB 262 billion, RMB 324 billion, and RMB 394 billion, respectively, with adjusted net profits expected to be RMB 0.5 billion, RMB 5.3 billion, and RMB 13.6 billion [5][11]. - The report anticipates a continued narrowing of losses through operational efficiency and algorithm optimization [2][11].

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company reported a revenue of 15.028 billion RMB (+22.6% YoY) and a net profit of 5.555 billion RMB (+27.1% YoY) for the year 2025, with innovative drugs contributing 12.354 billion RMB (+30.4% YoY), accounting for 82.2% of total revenue [1][7] - The growth is driven by both innovation and business development (BD), indicating a strong outlook for continued growth [1] Revenue Breakdown - Oncology segment revenue reached 9.974 billion RMB (+23% YoY), primarily due to the strong performance of core products like Amivantamab and milestone income from GSK [2] - Anti-infection revenue was 1.586 billion RMB (+8% YoY), driven by the sales of Adefovir [2] - CNS segment revenue was 1.310 billion RMB (-5% YoY), with the negative impact from centralized procurement on generic drugs largely mitigated [2] - Revenue from metabolic and other diseases surged to 2.158 billion RMB (+67% YoY), mainly due to milestone payments from Merck [2] R&D Progress - The company has 8+1 innovative drugs and 15+3 indications approved, with 40+ molecules in over 70 clinical trials [3] - Key pipelines include Amivantamab, HS-20093, HS-20089, HS-20094, and HS-20117, with several in Phase III clinical trials [3] International Collaboration - The company has achieved at least one high-quality external authorization each year for the past three years, accumulating 542 million USD in upfront payments and a total of 8.8 billion USD in potential revenue from five projects in Europe and the US [4] - Ongoing collaborations with GSK, Regeneron, and MSD are progressing positively, with several projects in various clinical stages [4] Profit Forecast and Valuation - The company’s net profit forecasts for 2026 and 2027 have been raised to 6.228 billion RMB and 6.602 billion RMB, respectively, reflecting an increase of 14% and 15% [5] - The target price is set at 43.68 HKD, based on a sum-of-the-parts (SOTP) valuation of 264.5 billion HKD [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company's performance is steadily growing, with the upward trend in uranium prices and the synchronization of long-term contract renewals releasing profit elasticity [5] - The company is expected to benefit from the global recovery in nuclear power, leading to sustained growth in natural uranium demand [7] - The company is backed by CGN Group, providing both market and resource advantages, with future uranium prices expected to remain high [7] Financial Summary - For 2026, the projected revenue is 11,849.71 million HKD, with a year-on-year growth rate of 72.5% [6] - The projected net profit attributable to shareholders for 2026 is 986.85 million HKD, reflecting a year-on-year increase of 118.0% [6] - The earnings per share for 2026 is estimated at 0.13 HKD, with a return on equity (ROE) of 17.8% [6] - The company’s total market capitalization is approximately 29,338.64 million HKD, with a debt-to-asset ratio of 47.64% [3][6] Operational Insights - In 2025, the company achieved a total uranium sales volume of approximately 4,611 tons, with a significant recovery in trading profits due to rising uranium prices in the second half of the year [7] - The average sales price for self-produced uranium was approximately 71.8 USD/pound, while the average sales price for international trade was about 74.7 USD/pound [7] - The company has locked in approximately 245 million HKD in trade profits from pending sales contracts by the end of 2025, providing a degree of performance assurance for the future [7]

Investment Rating - The investment rating for the company is "Neutral" [5] Core Views - The company reported a slight decline in revenue for 2025, with total revenue of 74 billion yuan, a decrease of 4.4% year-on-year. However, the net profit attributable to shareholders increased by 17.3% to 3.6 billion yuan, and the net profit attributable to ordinary shareholders rose by 35.5% to 2 billion yuan [1][3] - The total assets of the company grew by 5.0% year-on-year, reaching 1.72 trillion yuan by the end of 2025. The non-performing asset management segment saw a 4.1% increase in total assets, while the financial services segment also experienced a 4.1% growth [1] - The company benefited from investment income, particularly from its investment in Shanghai Pudong Development Bank, which contributed approximately 13.5 billion yuan to revenue. However, income from the acquisition and restructuring segments declined [2] - The credit cost ratio increased to 4.8%, up by 2.7 percentage points year-on-year, primarily due to pressure on asset quality and increased provisions for real estate inventory [2] Financial Forecasts - The company adjusted its profit forecasts, projecting net profits for 2026 and 2027 at 2.2 billion yuan and 2.4 billion yuan, respectively, with a diluted EPS of 0.06 yuan for these years. The current stock price corresponds to a PE ratio of 17.6 for 2026 [3][4] - The forecasted revenue for 2026 is 73.73 billion yuan, with a slight decline expected in subsequent years [4][7] - The return on equity (ROE) for 2025 was reported at 1.24%, with expectations for gradual improvement in the following years [4][7]

上 市 公 司 房地产 相关研究 2026 年 03 月 31 日 中国海外发展 (00688) ——业绩下滑符合预期，投资加码、融资改善 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2026 年 03 月 31 日 | | --- | --- | | 收盘价（港币） | 11.55 | | 恒生中国企业指数 | 8374.3 | | 52 周最高/最低（港币） | 15.12/11.36 | | H 股市值（亿港币） | 1,264.13 | | 流通 H 股（百万股） | 10,944.88 | | 汇率（港币/人民币） | 0.8830 | 一年内股价与基准指数对比走势： -15% 5% 25% HSCEI 中国海外发展 资料来源：Bloomberg 证券分析师 袁豪 A0230520120001 yuanhao@swsresearch.com 陈鹏 A0230521110002 chenpeng@swsresearch.com 联系人 陈鹏 A0230521110002 chenpeng@swsresearch.com 投资要点： 财务数据及盈利预测 | | 2024 | 2025 ...

Investment Rating - The investment rating for iFlytek Medical Technology (2506.HK) is not explicitly stated in the provided report, but the overall sentiment appears positive based on the financial projections and growth expectations [1]. Core Insights - The company reported a revenue of approximately 915 million yuan for 2025, reflecting a year-on-year growth of 24.66%. The adjusted net profit was -39 million yuan, with an adjusted net profit margin of -4.3%, which is an improvement of about 1.8 percentage points year-on-year [1]. - The GBC (General Business Collaboration) model is expected to drive growth across various business segments, with significant contributions from grassroots solutions, regional solutions, hospital solutions, and patient management services [4]. - The company has made substantial progress in expanding its services, with the AI assistant covering 806 districts and counties, and the smart family doctor program rapidly expanding nationwide [4]. Financial Summary - For 2025, the company achieved total revenue of 915 million yuan, with projected revenues of 1.198 billion yuan in 2026, 1.479 billion yuan in 2027, and 1.834 billion yuan in 2028, representing growth rates of 31%, 23%, and 24% respectively [6]. - The adjusted net profit is expected to turn positive in 2026, with estimates of 4 million yuan, followed by 64 million yuan in 2027 and 111 million yuan in 2028, indicating significant growth rates of 106%, 1451%, and 74% respectively [7]. - The gross margin for 2025 was reported at 50.45%, with expectations for gradual improvement in subsequent years [6]. Business Segment Performance - Revenue from grassroots solutions was 263 million yuan (up 11% year-on-year), regional solutions generated 206 million yuan (up 34%), hospital solutions brought in 173 million yuan (up 31%), and patient management services accounted for 273 million yuan (up 29%) [4]. - The company’s comprehensive gross margin decreased by approximately 4.55 percentage points, primarily due to increased delivery costs and purchased products, but specific segments like hospital solutions and patient management services showed improvements in gross margins [4]. Future Projections - The company anticipates a gradual increase in gross margins, driven by the rollout of AI pilot projects and rapid growth in consumer-facing business [4]. - The financial outlook suggests a recovery in profitability, with a projected return on equity (ROE) of 0.46% in 2026, increasing to 10.30% by 2028 [6].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company has achieved significant revenue and gross profit growth in 2025, with total revenue reaching 3.51 billion RMB, a year-on-year increase of 37.3%. The gross profit was 434 million RMB, up 44.2%, with an overall gross margin of 12.4%, reflecting a 0.6 percentage point improvement [3] - The company's core business, smart cockpit solutions, accounted for over 97% of total revenue in 2025, with revenue from this segment growing by 39.8% to 3.41 billion RMB [3] - The company focuses on high-end domain controllers, with revenue from this segment reaching 3.02 billion RMB, a 54.3% increase, making it the most critical business area [4] - The company has successfully penetrated the core supply chain of leading new energy vehicle manufacturers and is expected to expand its market share due to its technological and ecological advantages [5] Revenue Performance - In 2025, the company reported total revenue of 3.51 billion RMB, with a gross profit of 434 million RMB and a gross margin of 12.4% [3] - The revenue growth is primarily driven by the rapid increase in the delivery volume of smart cockpit domain controllers [3] - The company’s revenue projections for 2026, 2027, and 2028 are 5.66 billion RMB, 8.76 billion RMB, and 11.79 billion RMB, respectively, indicating a strong growth trajectory [5][6] Business Segmentation - Smart cockpit solutions are the core business, with revenue from this segment significantly contributing to overall performance [3] - The domain controller segment is highlighted as a key growth driver, with a focus on high-end products and partnerships with major OEMs [4] - Other segments, including connected services and additional business lines, showed mixed performance, with some experiencing declines [4][5]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company has shown a significant increase in net profit for the fiscal year 2025, with total revenue reaching 2.186 billion RMB, a year-on-year growth of 6.1%, primarily driven by an increase in resin lens shipments [2] - Gross profit for the same period was 917 million RMB, reflecting a 15.4% increase, with a gross margin of 42.0%, up 3.4 percentage points year-on-year, attributed to product mix upgrades and improved margins in both proprietary and OEM businesses [2] - The traditional lens business remains stable, with standard and functional lens revenues growing by 12.6% and 1.7% respectively, contributing over 80% to total revenue [2] Revenue Breakdown - Standard lens revenue for FY25 was 1.021 billion RMB, while functional lens revenue was 768 million RMB, both showing positive growth [2] - Custom lens revenue decreased by 0.6% to 393 million RMB, accounting for 18.0% of total revenue, primarily impacted by U.S. tariffs [3] XR Business Development - The company has entered mass production for key XR projects, recognized for its full-stack self-research capabilities and product performance, collaborating with around 20 leading smart glasses developers [4] - The company has launched a new production line for Neo Vision XR lenses, enhancing its capacity for customized development and mass production [4] - A joint venture with GoerTek has been established to focus on the development and production of customized lenses and optical components for smart glasses [4] Financial Projections - The company forecasts net profits of 712 million RMB for FY26 and 876 million RMB for FY27, with an additional projection of 1.062 billion RMB for FY28 [5] - Revenue is expected to grow significantly, with FY26 projected at 2.726 billion RMB, reflecting a 24.7% increase [6] - The company’s P/E ratios are projected to decrease from 29x in FY26 to 20x in FY28, indicating a favorable valuation trend [5] Market Position - As a leading domestic resin lens manufacturer, the company is expected to continue expanding its market share due to its high refractive index technology and C2M supply chain advantages [5] - The AI glasses market remains robust, with the company positioned to leverage its core technologies in ultra-thin lenses and waveguide integration [5]

Investment Rating - The report assigns a "Buy" rating to the company, with a current price of 617.50 HKD and a fair value of 762.22 HKD [5]. Core Insights - The company demonstrated strong brand value validation, with Q1 2026 operating performance exceeding expectations. The company reported a revenue of 27.3 billion RMB for FY25, representing a year-on-year growth of 221%, and a net profit of 4.87 billion RMB, up 230.5% year-on-year [8]. - The company is expected to achieve a revenue of 165-175 billion RMB in Q1 2026, with a net profit of 36-38 billion RMB, indicating a significant performance improvement compared to H1 2025 [8]. - The offline store revenue reached 226.5 billion RMB, growing by 204% year-on-year, while online revenue surged by 341.3% to 46.6 billion RMB, accounting for 17.1% of total revenue [8]. Financial Projections - The company’s main revenue is projected to grow from 8.51 billion RMB in 2024 to 61.99 billion RMB in 2028, with growth rates of 167.5%, 221.0%, 63.8%, 20.7%, and 14.8% respectively [4]. - The net profit attributable to shareholders is expected to increase from 1.47 billion RMB in 2024 to 12.78 billion RMB in 2028, with growth rates of 253.9%, 230.5%, 74.7%, 26.6%, and 18.7% respectively [4]. - The company’s EPS is forecasted to rise from 8.75 RMB in 2024 to 72.30 RMB in 2028, with a corresponding P/E ratio decreasing from 24.4 to 7.5 over the same period [4]. Market Position and Brand Strength - The company has strengthened its brand positioning, with an overlap rate of 82.4% with international luxury brands and a 74.3% increase in loyal members to 610,000 [8]. - Key products such as the Dragon and Phoenix incense pouch and the three-circle bracelet have received positive market feedback, contributing to the brand's high-end perception [8]. - The company has expanded its physical presence with 45 self-operated stores, adding 10 new stores and optimizing 9 existing ones, while also exploring overseas markets [8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The report highlights strong growth potential driven by the international version of "Heart Town" and the TapTap ecosystem, with expectations for significant revenue increases in the coming years [3][4] - The company achieved a revenue of 5.764 billion HKD in 2025, representing a year-on-year increase of 15%, and a net profit of 1.535 billion HKD, up 89% year-on-year [3] - The report projects net profits for 2026, 2027, and 2028 to be 2.006 billion HKD, 2.387 billion HKD, and 2.632 billion HKD respectively, with corresponding P/E ratios of 13.7, 11.5, and 10.4 [3][4] Financial Summary - Revenue for 2025 was 5,764 million HKD, with a year-on-year growth of 15% [4] - The net profit for 2025 was 1,535 million HKD, reflecting a significant increase of 89% year-on-year [3][4] - The gross margin for 2025 was 73.8%, an increase of 4.4 percentage points compared to the previous year [3] - The net margin improved to 28.7%, up 11.0 percentage points year-on-year [3] - The report forecasts revenues of 6,775 million HKD for 2026, 8,036 million HKD for 2027, and 8,725 million HKD for 2028, with respective year-on-year growth rates of 17.5%, 18.6%, and 8.6% [4]